NCT03582774Active, not recruitingPhase 3
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
Phase III Randomized Multicenter Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after surgery. 68Ga-PSMA-11 are taken up by cancer cells. Diagnostic procedures, such as PET/CT scans, may help find and diagnose prostate cancer and find out how far the disease has spread. Giving 68Ga-PSMA-11 with PET/CT may help doctors plan better for salvage radiation therapy in participants with recurrent prostate cancer.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 193 (estimated)
- First submitted
- 19 Jun 2018
- Start date
- 12 Jul 2018
- Primary completion date
- 12 Jul 2027
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT03582774
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 193
- From 12 Jul 2018 to the primary completion date, 12 Jul 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Androgen deprivation therapy (ADT) within 3 months before 68Ga-PSMA-11 PET/CT.
- Concurrent systemic therapy for prostate cancer with investigational agents.
Other illness
- Contraindications to radiotherapy (including active inflammatory bowel disease).
Other
- Extra-pelvic metastasis on any imaging or biopsy.
Who the study is looking for
- Histopathology proven prostate cancer.
- Planned SRT for recurrence after primary prostatectomy.
- Prostate-specific antigen (PSA) \>= 0.1 ng/ml at time of enrollment.
- Willingness to undergo radiotherapy.
- Treating radiation oncologist intends to incorporate 68Ga-PSMA-11 PET/CT findings into the radiotherapy plan if patient undergoes 68Ga-PSMA-11 PET/CT.
Sex: Male · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| UCSF Medical Center-Mount Zion Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
Related publications
- Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy.J Natl Compr Canc Netw · 2026 · PMID 41698328
This page is information, not medical advice. Discuss any trial with your doctor.